Unilateral renal agenesis and urethral atresia associated with ergotamine intake during pregnancy
Gamze Demirel1, Serife Suna Oguz, Omer Erdeve
1Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey. kgamze@hotmail.com
Abstract:
Ergotamine, an ergot alkaloid, used for the treatment and prevention of migraine attacks, is considered as a teratogenic drug and, therefore, should be avoided in pregnancy. Here, we report a newborn infant with unilateral renal agenesis, urethral atresia, and pulmonary hypoplasia associated with the use of ergotamine for the treatment of migraine attacks at early pregnancy. Genitourinary anomalies in association with ergotamine usage were rarely reported and this was the third case of renal agenesia in association with ergotamine usage in literature. We suggest that ergotamine teratogenicity may be dose dependent and should be avoided in pregnancy for the possibility of genitourinary anomalies.
Related Concept Videos
Teratogenicity
Drugs Affecting Neurotransmitter Release or Uptake
Acute Kidney Injury II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hormonal Regulation
Drugs Affecting Neurotransmitter Synthesis

